Adoptive Chemoimmunotherapy Using Activated αβ T Cells for Stage IV Colorectal Cancer.
Yoshida Y1, Naito M2, Yamada T2, Aisu N2, Daibo K2, Mera T2, Tanaka T3, Naito K4, Yasumoto K4, Kamigaki T4, Goto S4, Yamashita Y2, Hasegawa S2
Anticancer Res. 2016 Jul;36(7):3741-6.
Adoptive immunotherapy of cancer is evolving with the development of novel technologies that generate proliferation of large numbers of αβ and γδT cells. We evaluated the safety and efficacy of the combination of adoptive immunotherapy using αβ T cells with chemotherapy for stageIVcolorectal cancer (CRC).
PATIENTS AND METHODS:
Fifteen patients with advanced or recurrent CRC received XELOX + bevacizumab + ex vivo expanded αβ T lymphocytes as a first-line chemoimmunotherapy.
Median age of the 15 patients (4 men, 11 women) was 65 years (range=49-80). Median progression-free survival was 21.3 months. Response rate was 80% (complete response (CR)=26.7%, partial response (PR)=53.3%, stable disease (SD)=20% and progressive disease (PD)=0%). Most adverse events were mild to moderate regarding their intensity and immunotherapy-associated toxicity was minimal.
Combination of adoptive αβ T cell immunotherapy with chemotherapy for stageIV CRC is feasible and safe.